The global scale-up of antiretroviral (ARV) therapy (ART) has led to dramatic reductions in
HIV-1 mortality and incidence. However, HIV drug resistance (HIVDR) poses a potential …

The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Background Previously reported post hoc multivariable analyses exploring predictors of
confirmed virologic failure (CVF) with cabotegravir+ rilpivirine long-acting (CAB+ RPV LA) …

Background Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was
recently approved in the United States for the treatment of human immunodeficiency virus …

Background Contemporary antiretroviral therapies (ART) and management strategies have
diminished both human immunodeficiency virus (HIV) treatment failure and the acquired …

ABSTRACT Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of
HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory …

Abstract Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a
human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI …

The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the
safety and efficacy of 50 mg dolutegravir+ abacavir/lamivudine versus efavirenz/tenofovir …

The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last
published in January 2017. The mutations listed are those that have been identified by …

Background Characterizing the mutations selected by the integrase strand transfer inhibitor
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …